Sera Prognostics, Inc.

Other

Alzheimer's Institute of America, Inc.

Andrew Gassman

Tracey Cristine Fleischer

Paul Edward Kearney

John Jay Boniface

Ashoka Dharmapriya Polpitiya

Durlin Edward Hickok

Gregory Charles Critchfield

Chad Bradford

Jeff Flick

John P Manfredi

Christine A Klein

Mark B Anderson

Warren S Weiner

Rachel M Slade

Ruth J Walton

Kenton Zavitz

Yevgeniya Klimova

Robert J Halter

Jon Adam Willardsen

Ashantai J Yungai

Daniel M Cimbora

Leena Bhoite

Jeffrey S Flick

Vijay R Baichwal

Damon I Papac

Ashoka Polpitiya

The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. Also provided is a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female.

Biomarker pairs for predicting preterm birth

The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport).

Compounds for Alzheimer's disease

The invention relates to methods of treating diseases, particularly cancers, that respond favorably to the inhibition of Nicotinamide phosphoribosyltransferase (Nampt); it also relates to therapeutic methods that utilize Nampt inhibitors in combination with NAD biosynthesis precursors to intentionally kill cancer cells while limiting or minimizing toxicity to normal host cells; and it relates to methods of identifying cancers that will be most responsive to treatment with Nampt inhibitors, particularly when administered in combination with nicotinic acid.

Therapeutic and diagnostic methods

Growing community of inventors

Salt Lake City, UT, United States of America

Andrew Gassman